Comparison · NCT01227928-8eea1c9c
Pazopanib 800 Milligrams vs Placebo: Number of Participants With Any Grade 3 or 4 AE
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Pazopanib 800 Milligrams vs Placebo: Number of Participants With Any Grade 3 or 4 AE. Trial comparisons, record NCT01227928-8eea1c9c. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01227928-8eea1c9c
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.542 | 0.427 | 0.652 | wilson | |
| Risk in group 2 | 0.111 | 0.0574 | 0.204 | wilson | |
| Risk difference, group 1 minus group 2 | 0.431 | 0.283 | 0.553 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 4.88 | 2.45 | 9.69 | log | |
| Odds ratio, group 1 over group 2 | 9.45 | 3.97 | 22.5 | log | |
| Number needed to treat, for one more participant with the outcome on Pazopanib 800 Milligrams than on Placebo | 2.32 | 1.81 | 3.53 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Pazopanib 800 Milligrams | Participants received pazopanib 800 milligrams administered orally once daily for up to 24 months. | 39 | 72 | OG001 |
| Group 2 | Placebo | Participants received matching placebo administered orally once daily for up to 24 months. | 8 | 72 | OG000 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Number of Participants With Any Grade 3 or 4 AE
- Description
An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. The NCI Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 3.0 was used to grade AEs per the following scale to assess severity: Grade 1, mild; Grade 2, moderate; Grade 3, severe; Grade 4, life-threatening or disabling AE; Grade 5, death related to AE.
- Time frame
- From Week 1 until the end of the treatment period (up to Study Week 108)
- Population
All Treated Population: all randomized participants who received at least one dose of investigational product. Treatment assignments in the All Treated Population were based on the actual treatment received, if different from the randomized treatment. The cut off for these data was January 10, 2014.
Source ClinicalTrials.gov
Trial
- Title
- Efficacy and Safety of Pazopanib Monotherapy After First-line Chemotherapy in Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Asian Women
- NCT number
- NCT01227928
- Phases
- PHASE2
- Conditions
- Neoplasms, Ovarian
- Interventions
- Pazopanib, Placebo comparator
- Lead sponsor
- GlaxoSmithKline
- Results first posted
- 2013-06-04
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT01227928?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT01227928-8eea1c9c